Michael H. Carrel has served on the board of Axonics since March 4, 2019.

Mr. Carrel is President and Chief Executive Officer of AtriCure (NASDAQ: ATRC), a medical device company that provides innovative solutions for the treatment of atrial fibrillation (AFib) and related conditions. Since joining AtriCure, the company has significantly invested in groundbreaking clinical trials for the treatment of AFib, left atrial appendage management and pain management; expanded its market presence within Europe and Asia; and grown the global employee base from 200 to over 600 employees. Under his leadership, AtriCure has acquired two companies, Estech and nContact, adding leading ablation technologies to further its market position worldwide. Mr. Carrel also serves on the Board of Medical Device Manufacturers Association (MDMA).

Before joining AtriCure, Mr. Carrel was President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company, President and CEO of Zamba Corp., a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug-and-play broadband wireless access systems.

Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the Wharton School at the University of Pennsylvania. Mr. Carrel has been the Chairman of the Board of Axonics since 2020.